Ann Arbor, MI – February 21, 2023

Genomenon Appoints Vice President of Engineering to Leadership Team

John Battles joins executive team to lead and expand product and technical opportunities

Genomenon®, an AI-driven genomics company, announced today that John Battles has been appointed Vice President of Engineering. Battles will be responsible for leading the technical vision and implementation to deliver leading edge precision medicine solutions.

Before joining Genomenon, Battles led many successful endeavors, including development of the Precision Behavioral Technology Platform at Genomind and a new bioinformatics data management and analysis platform at Q2 Solutions. He brings over 25 years of experience in leading software development efforts in the genomics, life sciences, and pharma domains.

“We are delighted to welcome John to the Genomenon executive leadership team,” said Mike Klein, chief executive officer at Genomenon. “His extensive experience in leading and managing effective software development teams will be critical in helping us develop new product and technical opportunities that we will leverage to grow Genomenon.”

Battles holds a M.S. in Biochemistry from Purdue University, a B.A. in Biology from Saint Joseph’s College, and a Credential of Readiness in Accounting & Business Management from Harvard Business School Online.

“I’m excited to be joining the leadership team at Genomenon,” said Battles. “To take part in revolutionizing the way genomic information is utilized for patient care and pharmaceutical advancements is very inspiring—I’m looking forward to the future.”


About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

Learn more about Genomenon at and follow them on LinkedIn and Twitter.